Pieris Pharmaceuticals Announces Dosing of First Patient in Phase I Combination Trial for PRS-343 Plus Anti-PD-L1 Immunotherapy
pharmaceutical investing Pieris Pharmaceuticals Appoints Ingmar Bruns, M.D., Ph.D., as Vice President of Clinical Development
Heliostar Metals to Present at the Precious Metals & Critical Minerals Virtual Investor Conference October 14
Precious Metals & Critical Minerals Virtual Investor Conference Agenda Announced for October 13th - 15th
